Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part C

Phase 1/2Terminated

2 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Celiac Disease

Conditions

Celiac Disease

Trial Timeline

Nov 15, 2022 → May 19, 2025

NCT ID

NCT05574010

About Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part C

Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part C is a phase 1/2 stage product being developed by Pfizer for Celiac Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05574010. Target conditions include Celiac Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05574010	Phase 1/2	Terminated	Nov 15, 2022	May 19, 2025	Celiac Disease

Competing Products

17 competing products in Celiac Disease

See all competitors

Product	Company	Stage	Hype Score
DONQ52 + Placebo	Chugai Pharmaceutical	Phase 1	29
Placebo DONQ52 + DONQ52	Chugai Pharmaceutical	Phase 2	42
Placebo + RO5459072	Roche	Phase 1	29
CCX282-B + Placebo	Amgen	Phase 2	35
AMG 714 + Placebo	Amgen	Phase 2	35
AMG 714 + Placebo	Amgen	Phase 2	35
AMG 714	Amgen	Pre-clinical	26
KAN-101 + Placebo	Pfizer	Phase 2	35
Ritlecitinib + Placebo	Pfizer	Phase 2	42
PRV-015	Sanofi	Phase 2	35
TIMP-GLIA	Takeda Pharmaceutical	Phase 1	29
TIMP-GLIA + Placebo	Takeda Pharmaceutical	Phase 2	35
PTG-100 + Placebo	Protagonist Therapeutics	Phase 1	26
Rifaximin + Placebo	Bausch Health	Pre-clinical	20
Latiglutenase	Allergy Therapeutics	Phase 2	21
BL-7010 + Placebo	BioLineRx	Phase 1/2	22
VTP-1000	Barinthus Biotherapeutics	Phase 1	26